Cephalon/Alkermes Vivitrex User Fee Date Extended
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20
You may also be interested in...
Alcohol Dependence Treatment Vivitrol “Approvable”
Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.
Alcohol Dependence Treatment Vivitrol “Approvable”
Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.
Alkermes Submits Vivitrex NDA
Alkermes' Vivitrex would be the first alcohol dependence treatment available in a once-monthly injection if FDA approves the NDA submitted March 31